Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback